EcoVision

What Prompted This Reflection on ESG and AI? Following my visit yesterday to the 3rd China Tech Driving Innovation Summit at Hotel ICON (14 May 2026), I found myself reflecting on how quickly the ESG landscape is evolving alongside technological advancement. The seminar brought together diverse perspectives across AI, cybersecurity, and enterprise innovation, offering a timely lens into how sustainability is being reshaped in practice—not just in theory. My sincere thanks to Emil Chan for the...

The pharmaceutical industry is undergoing a structural shift where ESG considerations are no longer peripheral but central to growth strategies. Increasing regulatory pressure, investor scrutiny, and stakeholder expectations are compelling companies to embed sustainability into core operations. In 2025, over 70% of global pharmaceutical firms reported enhanced ESG disclosures, reflecting a broader move toward transparency and accountability. Environmental concerns such as carbon-intensive...

The New IPO Reality: ESG Is No Longer Optional In 2026, ESG and sustainability have moved from a “nice-to-have” narrative to a core determinant in IPO reality & readiness. (besides compliance and regulatory requirements...) Institutional investors are increasingly embedding ESG metrics into due diligence frameworks, with over 80% of global asset managers now incorporating sustainability factors into investment decisions. Companies preparing to go public are expected to demonstrate not only...